The distal enzymatic step in the process of glucose output is catalyzed by the glucose-6-phosphatase (Glc-6-Pase) complex. The recently cloned catalytic unit of this complex has been shown to be regulated by insulin, dexamethasone, cAMP, and glucose. Using a combination of intralipid and/or nicotinic acid infusions and a pancreatic clamp technique, we maintained plasma free fatty acids (FFAs) at three different levels (0.26 ± 0.07, 0.56 ± 0.09, and 1.59 ± 0.12 mmol/1) in the presence of well-controlled hormonal and metabolic conditions. An increase in the plasma FFA concentration within the physiological range caused a rapid, greater than threefold increase in the mRNA and protein levels of the catalytic subunit of Glc-6-Pase in the liver. These data indicate that the in vivo gene expression of Glc-6-Pase in the liver is regulated by circulating lipids independent of insulin and thus that prolonged hyperlipidemia may contribute to the increased production of glucose via increased expression of this protein. G lucose-6-phosphatase (Glc-6-Pase) catalyzes the final enzymatic step for hepatic gluconeogenesis and glycogenolysis (1). Glc-6-Pase is a complex of proteins with the catalytic portion deeply embedded in the endoplasmic reticulum (ER) (1). Because of its intracellular localization, it has long been suggested that the lipid composition of the ER membrane would play a pivotal role in the regulation of Glc-6-Pase activity. Indeed, some recent reports have shown an acute inhibitory effect of fatty acyl-CoA (2,3) and fatty acid ester (4,5) on Glc-6-Pase activity. In contrast, increased hepatic Glc-6-Pase activity has been reported to follow prolonged increases in dietary saturated fatty acids (6).Important interactions between glucose and lipid metabolism have been demonstrated in skeletal muscle (7-9), liver (8-10), and 3-cells (11). In particular, numerous studies have shown that the rate of endogenous glucose production is closely related to the circulating plasma FFA concentrations ER, endoplasmic reticulum; FFA, free fatty acid; PMSF, phenylmethylsulfonyl fluoride; SSC, sodium chloride-sodium citrate. (9,10,12,13) and that the majority of individuals with NIDDM have increased 24-h plasma FFA profiles (14). While the acute effects of an increase in plasma FFA availability are likely to be largely caused by its known stimulatory effect on gluconeogenesis (15), much less is known regarding the long-term consequences of increased hepatic availability of FFAs.Indeed, dietary fatty acids have been shown to regulate the gene expression of pancreatic GLUT2 and glucokinase (16), and long-chain fatty acids can induce the expression of the genes for the adipocyte fatty acid-binding protein aP2 (17) and liver carnitine palmitoyltransferase I (CPT I) (18). Additionally, the expression of a number of hepatic lipogenic, glycolytic, and gluconeogenic genes is regulated by polyunsaturated fatty acids at the transcriptional level (19,20).Since Glc-6-Pase mRNA and activity increase in metabolic conditions associated with high ...